by Thomas R. Collins: Leading transplant experts say they’ve had a good experience using the once-a-day tacrolimus regimen, reporting better patient adherence compared to the twice-a-day version, along… read more.
Risk of living donor transplants can be mitigated by Thomas R. Collins Making living donor transplants less risky through new and innovative approaches is the best way to… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
Dr Sridhar Chaganti, University Hospital, Birmingham NHS Foundation Trust, UK. by Christine Clark: In general the outcomes of treatment for diffuse large B-cell lymphoma (DLBCL) are good –… read more.
Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.
Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.
Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.
Advertisment